COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB
Abstract
Authors
K. Garces C. Thorne G. Boire A. Chow M. Poulin-Costello V. Walker B. Haraoui